Invitae Corporation (NYSE:NVTA):
Invitae to announce third quarter 2017 Financial Results and Host Conference Call on November 6, 2017.
The company is now down by 0.50%% since yesterday’s close of 9.92.
Invitae Corporation, launched on January 13, 2010, utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Business’s products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management..
The stock last traded at $9.87 just above $9.50, the stock’s 50 day moving average and which is just a bit higher than the 200 day moving average of $9.50. The 50 day moving average went up $0.37 or +3.89% whereas the 200 day average was up by +3.89%.
As of the latest earnings report the EPS was $-2.73 and is expected to be $-2.35 for the current year with 43,544,000 shares currently outstanding. Analysts expect next quarter’s EPS will be $-0.51 with next year’s EPS projected to be $-1.33.
Traders are feeling more bearish on shares of Invitae Corporation lately if you evaluate the rise in short interest. The firm recorded a rise in short interest between September 15, 2017 and September 29, 2017 of 0.90%. Short interest grew from 2,387,386 to 2,408,976 over that period. With short interest at 2,408,976 and short average daily volume at 221,172, the short-interest ratio is 11.0 and the short interest percentage is 0.06% as of September 29.